Search Results - "Childs, B H"

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT by Hochster, H.S., Grothey, A., Hart, L., Rowland, K., Ansari, R., Alberts, S., Chowhan, N., Ramanathan, R.K., Keaton, M., Hainsworth, J.D., Childs, B.H.

“…Oxaliplatin is an integral component of colorectal cancer treatment, but its use is limited by neurotoxicity. The Combined Oxaliplatin Neurotoxicity Prevention…”
Get full text

Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation : Effect of patient age and donor leukocyte infusions by SMALL, T. N, PAPADOPOULOS, E. B, HELLER, G, FAZZARI, M, KERNAN, N, MACKINNON, S, SZABOLCS, P, YOUNG, J. W, O'REILLY, R. J, BOULAD, F, BLACK, P, CASTRO-MALASPINA, H, CHILDS, B. H, COLLINS, N, GILLIO, A, GEORGE, D, JAKUBOWSKI, A

“…Unrelated bone marrow transplantation (BMT) is often complicated by fatal opportunistic infections. To evaluate features unique to immune reconstitution after…”
Get full text

Adoptive Immunotherapy Evaluating Escalating Doses of Donor Leukocytes for Relapse of Chronic Myeloid Leukemia After Bone Marrow Transplantation: Separation of Graft-Versus-Leukemia Responses From Graft-Versus-Host Disease by Mackinnon, Stephen, Papadopoulos, Esperanza B., Carabasi, Matthew H., Reich, Lilian, Collins, Nancy H., Boulad, Farid, Castro-Malaspina, Hugo, Childs, Barrett H., Gillio, Alfred P., Kernan, Nancy A., Small, Trudy N., Young, James W., O'Reilly, Richard J.

“…Infusions of large numbers (>108/kg) of donor leukocytes can induce remissions in patients with chronic myeloid leukemia (CML) who relapse after marrow…”
Get full text

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma by Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S.E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B.H., Zinzani, P.L.

“…Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. This phase II study evaluated the…”
Get full text

Antileukemia activity of a natural killer cell line against human leukemias by YING YAN, STEINHERZ, P, KLINGEMANN, H.-G, DENNIG, D, CHILDS, B. H, MCGUIRK, J, O'REILLY, R. J

“…We describe here the in vitro and in vivo antileukemia activity of a recently described natural killer (NK) cell line (NK-92), which has features of human…”
Get full text

Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones by ARATEN, D. J, BESSLER, M, MCKENZIE, S, CASTRO-MALASPINA, H, CHILDS, B. H, BOULAD, F, KARADIMITRIS, A, NOTARO, R, LUZZATTO, L

“…PNH is characterized by expansion of one or more stem cell clones with a PIG-A mutation, which causes a severe deficiency in the expression of…”
Get full text

Activity of larotrectinib in TRK fusion lung cancer by Drilon, A., Kummar, S., Moreno, V., Patel, J., Lassen, U., Rosen, L., Childs, B.H., Nanda, S., Cox, M.C., Ku, N.C., Farago, A.F.

Get full text

Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1 by Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Özcan, M., Kosinova, M., Provencio, M., Magagnoli, M., Bouabdallah, K., Heo, D. S., Diong, C. P., Munoz, J., Cao, A., Hiemeyer, F., Odongo, F., Garcia‐Vargas, J., Childs, B. H., Zinzani, P. L.

Get full text

CHRONOS‐3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (INHL) by Zinzani, P. L., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M.‐C., Baker, R., Bondarenko, I., Zhang, Q., Feng, J., Geissler, K., Lazaroiu, M., Saydam, G., Szomor, Á., Bouabdallah, K., Galiulin, R., Uchida, T., Mongay Soler, L., Cao, A., Hiemeyer, F., Mehra, A., Childs, B. H., Shi, Y., Matasar, M. J.

Get full text

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS‐3 TRIAL by Zinzani, P. L., Özcan, M., Sapunarova, K., Jurczak, W., Hamed, A., Bouabdallah, K., Saydam, G., Geissler, K., Szomor, Á., Lazaroiu, M., Salar, A., Tempescul, A., Nalcaci, M., Gercheva, L., Egyed, M., Panayiotidis, P., Mongay Soler, L., Cao, A., Phelps, C., H Childs, B., J Matasar, M.

Get full text

Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis by MICHEL, G, BOULAD, F, KERNAN, N. A, O'REILLY, R. J, SMALL, T. N, BLACK, P, HELLER, G, CASTRO-MALASPINA, H, CHILDS, B. H, GILLIO, A. P, PAPADOPOULOS, E. B, YOUNG, J. W

“…Leukemia cutis (LC) is a rare feature of acute myeloblastic leukemia (AML). Little information is available regarding its prognostic influence on…”
Get full text

High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors by ABREY, L. E, ROSENBLUM, M. K, PAPADOPOULOS, E, CHILDS, B. H, FINLAY, J. L

“…High dose chemotherapy (HDCT) with autologous (bone marrow or peripheral blood) stem cell rescue (ASCR) has had success in the treatment of some malignant…”
Get full text

T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease by Papadopoulos, Esperanza B., Carabasi, Matthew H., Castro-Malaspina, Hugo, Childs, Barrett H., Mackinnon, Stephen, Boulad, Farid, Gillio, Alfred P., Kernan, Nancy A., Small, Trudy N., Szabolcs, Paul, Taylor, Joanne, Yahalom, Joachim, Collins, Nancy H., Bleau, Sharon A., Black, Patricia M., Heller, Glenn, Reilly, Richard J. O', Young, James W.

“…Thirty-one consecutive patients with acute myelogenous leukemia (AML) in first complete remission and 8 with AML in second complete remission received T…”
Get full text

Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation by Papadopoulos, Esperanza B, Ladanyi, Marc, Emanuel, David, Mackinnon, Stephen, Boulad, Farid, Carabasi, Matthew H, Castro-Malaspina, Hugo, Childs, Barrett H, Gillio, Alfred P, Small, Trudy N, Young, James W, Kernan, Nancy A, O'Reilly, Richard J

“…In marrow-transplant recipients, lymphoproliferative disorders associated with Epstein-Barr virus (EBV) usually present as malignant B-cell lymphomas of donor…”
Get full text

RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells by Bajenova, O, Tang, B, Pearse, R, Feinman, R, Childs, B H, Michaeli, J

“…These studies explore the molecular effect of arsenicals on MM cells. Freshly isolated cells derived from patients with advanced, chemo-refractory myeloma as…”
Get full text

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study by Dreyling, Martin, Santoro, Armando, Mollica, Luigina, Leppä, Sirpa, Follows, George, Lenz, Georg, Kim, Won Seog, Nagler, Arnon, Dimou, Maria, Demeter, Judit, Özcan, Muhit, Kosinova, Marina, Bouabdallah, Krimo, Morschhauser, Franck, Stevens, Don A., Trevarthen, David, Munoz, Javier, Rodrigues, Liana, Hiemeyer, Florian, Miriyala, Ashok, Garcia‐Vargas, Jose, Childs, Barrett H., Zinzani, Pier Luigi

“…Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings regarding fatal/serious toxicities. The approved intravenous PI3K inhibitor…”
Get full text

485PGrowth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients by Italiano, A, Nanda, S, Keating, K, Childs, B H, Fellous, M, Drilon, A, Hyman, D M

“…Abstract Background Randomized controlled trials are not feasible for rare cancer populations particularly when the investigational drug targets a molecular…”
Get full text

Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors by Macy, M., Cash, T., Pinto, N., Pressey, J.G., Szalontay, L., Furman, W.L., Bukowinski, A., Foster, J.H., Friedman, G.K., HaDuong, J., Fox, E., Weigel, B.J., Grevel, J., Huang, F., Phelps, C., Childs, B.H., Chung, J., Chaturvedi, S., Schulz, A., DuBois, S.G.

Get full text

From boardroom to bedside: a comprehensive organizational healthcare ethics by Childs, B H

“…While it is beyhond the scope of this paper to detail the reasons for those factors that militate against a robust organizational ethic, at least three issues…”
Get full text

Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria by Araten, David J., Swirsky, David, Karadimitris, Anastasios, Notaro, Rosario, Nafa, Khedoudja, Bessler, Monica, Thaler, Howard T., Castro‐Malaspina, Hugo, Childs, Barrett H., Boulad, Farid, Weiss, Mark, Anagnostopoulos, Nikolaos, Kutlar, Abdullah, Savage, David G., Maziarz, Richard T., Jhanwar, Suresh, Luzzatto, Lucio

“…Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by the expansion of a haematopoietic stem cell clone with a PIG‐A mutation (the PNH clone) in an…”
Get full text